Background: Transgender and other gender diverse (TGD) youth of color experience stigma within healthcare. Gender affirmation can be a resilience resource; however, little is known about gender affirmation within healthcare.
Purpose: This study explores TGD youth of color's experiences of stigma and gender affirmation across the entire healthcare experience and their role on motivation to seek care.
Methods: In 2015, cross-sectional surveys and individual in-depth interviews were conducted among 187 TGD youth ages 16-24 living in 14 U.S. cities. Analyses followed a mixed-methods design whereby 33 participants were purposively selected for a qualitative phenomenological analysis based on quantitatively reported gender affirmation needs. Subsequent quantitative analyses examined how healthcare use differed by access to gender affirmation.
Results: Participants qualitatively described experiencing stigma across multiple healthcare settings (e.g., primary care, emergency care, medical gender affirmation), including before (finding providers, scheduling), during (waiting rooms, provider interactions), and after (pharmacy) healthcare visits. Participants who quantitatively reported access to gender-affirming healthcare still described negative healthcare experiences, either because they accessed multiple healthcare services or because of prior negative experiences. Stigma and gender affirmation (both inside and outside of healthcare) influenced motivation to seek care, with variation depending on the type of care. Quantitative analyses confirmed these findings; access to gender affirmation differed for participants who delayed primary care vs. those who did not, but did not vary based on participants' use of medical gender affirmation.
Conclusions: Findings highlight the importance of promoting gender-affirming healthcare environments to increase access to care for TGD youth of color.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601040 | PMC |
http://dx.doi.org/10.1093/abm/kaab011 | DOI Listing |
BMC Med Ethics
December 2024
School of Public Health and Social Policy, Faculty of Human and Social Development, University of Victoria, Victoria, BC, Canada.
Background: Some transgender and nonbinary people undergo phalloplasty and/or metoidioplasty as part of their medical transition process. Across surgical disciplines, a variety of resources are used to assist patients who are preparing for surgeries, including educational materials, workshops, peer support, and lifestyle changes. For gender-affirming surgeries, patients undergoing assessments to discern whether they are ready to undergo the surgery, and to assist them in achieving preparedness when needed.
View Article and Find Full Text PDFTransgend Health
December 2024
Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.
Injectable estrogens are options for gender-affirming hormone therapy per guidelines, which suggest intramuscular dosages of 5-30 mg every 2 weeks or 2-10 mg weekly with estradiol cypionate or valerate interchangeably. Data among transgender and gender-diverse patients are limited due to local unavailability and concerns around laboratory assay variability and estradiol (E2) level fluctuation. We note a concerning trend where patients are prescribed high-dose injections based on the guidelines leading to serum E2 levels well above the range recommended in the same guidelines.
View Article and Find Full Text PDFTransgend Health
December 2024
School of Teacher Education and Leadership, Utah State University, Logan, Utah, USA.
Purpose: In this article, we describe and illustrate the victimization experiences of transgender immigrants in the U.S. detention system.
View Article and Find Full Text PDFTransgend Health
December 2024
Child and Youth Psychiatry, Centre for Addiction and Mental Health, Toronto, Canada.
Purpose: This study describes Thai transfeminine individuals' exogenous hormone use.
Methods: During the period May-July 2017, a survey was conducted among Thai transfeminine adults (=181) who reported their exogenous hormone use, age at onset of use, brands used, where they obtained hormones, and discontinuation of use.
Results: Most participants (86.
Transgend Health
December 2024
Andrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
Purpose: There is a paucity of data on the safety and efficacy of long-term testosterone (T)-based gender-affirming hormone therapy (GAHT) on anthropometric parameters, body composition, and glycolipid metabolism in assigned female at birth (AFAB) persons. The purpose of this study was to provide an updated meta-analysis on this topic.
Methods: We searched PubMed, Scopus, and Cochrane Library for relevant studies.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!